文献速递咽喉与嗓音

声带内注射曲拉法明治疗年龄相关声带萎缩的倾向性评分匹配疗效研究

Efficacy of Intracordal Trafermin Injection Using Propensity Score Matching in Age-Related Vocal Fold Atrophy.
PubMed 文献 · Laryngoscope · 2026-01-11

本研究在东京嗓音中心回顾性纳入年龄相关声带萎缩患者,比较声带内注射曲拉法明(ITI)与标准嗓音治疗(VT)的疗效。经倾向性评分匹配后,ITI组嗓音改善显著优于VT组(p=0.023)。结论认为ITI对改善年龄相关声带萎缩的嗓音结局有效。

要点

  • 倾向性评分匹配后,ITI组嗓音改善显著优于VT组(p=0.023)。
  • 匹配前两组年龄与性别分布不均衡,匹配后基线特征平衡(标准化均数差<0.1)。
  • ITI组注射后平均录音期40.98天,VT组初始治疗后平均录音期79.91天。

核心结论

  • 声带内注射曲拉法明似可有效改善年龄相关声带萎缩患者的嗓音结局。

研究设计与样本

  • 回顾性研究,2014年7月至2024年12月于东京嗓音中心开展,ITI组197/210例,VT组412/488例,采用倾向性评分匹配比较两组。

主要发现

  • 匹配前ITI组平均年龄65.30岁(SD 14.01)、女性48例(24.67%),VT组平均年龄64.81岁(SD 14.42)、女性246例(59.71%)。
  • 匹配前t检验显示两组结局无显著差异。
  • 匹配后(C统计量=0.746)基线特征平衡(标准化均数差<0.1),t检验显示ITI组嗓音改善显著更优(p=0.023)。

关键数值与推荐

  • 主要结局为VHI改善值,即治疗后与治疗前评分之差。
  • ITI组平均嗓音录音期为注射后40.98天,VT组为初始VT后79.91天。

临床怎么用

  • 对于年龄相关声带萎缩患者,声带内注射曲拉法明可作为改善嗓音的备选干预。
  • 需结合患者特征与嗓音治疗安排,个体化选择ITI或VT。

局限性

  • 为回顾性研究,需前瞻性干预试验及与其他注射剂的对比分析以确定最有效治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HYPOTHESIS: We hypothesized that Intracordal Trafermin Injection (ITI) provides greater voice improvement than standard voice therapy (VT) in age-related vocal fold atrophy (ARVA). To evaluate the efficacy of ITI versus VT using propensity score matching (PSM) in ARVA. METHODS: This retrospective study was conducted at the Tokyo Voice Center between July 2014 and December 2024 using medical records in ARVA. The intervention group comprised 197 of 210 patients who received ITI (mean voice recording period: 40.98 days after injection). The control group included 412 of 488 patients who underwent voice therapy (VT) between April 2015 and December 2024 (mean voice recording period: 79.91 days after initial VT). The primary outcome was defined as the improvement in VHI, calculated as the difference between post-treatment and pre-treatment scores. PMS was used to compare ITI and VT. RESULTS: Before PSM, the mean age and sex (female) were 65.30 years (standard deviation [SD], 14.01) and 48 patients (24.67%) in the ITI group and 64.81 years (SD, 14.42) and 246 patients (59.71%) in the VT group, respectively. T-tests revealed no significant differences in outcomes. After PSM (C-statistic = 0.746), the baseline characteristics were balanced (standardized mean difference < 0.1). Post-matching, t-tests revealed significantly greater voice improvement in the ITI group (p = 0.023). CONCLUSION: ITI appears effective for improving voice outcomes in ARVA. Future studies should include prospective interventional trials and comparative analyses with other injectable agents to determine the most effective treatment.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Hasegawa T, Watanabe Y. Efficacy of Intracordal Trafermin Injection Using Propensity Score Matching in Age-Related Vocal Fold Atrophy. Laryngoscope. 2026. PMID: 41521571. doi:10.1002/lary.70360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。